Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA
XDNA was delisted on the 30th of November, 2023.
0 hedge funds and large institutions have $0 invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
4.3% less ownership
Funds ownership: 4.3% → 0% (-4.3%)
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $95.8K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$92.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.11K |
XDNA Hedge Fund Activity: Q4 2023 in Review
0 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q4 2023, worth a combined $0 — down 100% from $95.8K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XDNA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Jane Street, exiting entirely with an estimated $92.6K sold.
- 0 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q4 2023, down from 2 in Q3 2023.
- Funds reported $0 of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF seller in Q4 2023 was Jane Street, an estimated $92.6K sold.
Based on aggregated 13F filings for Q4 2023.